Home >> Research Area >> Benzofuroxan

Benzofuroxan

CAS# 480-96-6

Benzofuroxan

Catalog No. BCC8852----Order now to get a substantial discount!

Product Name & Size Price Stock
Benzofuroxan:5mg Please Inquire In Stock
Benzofuroxan:10mg Please Inquire In Stock
Benzofuroxan:20mg Please Inquire In Stock
Benzofuroxan:50mg Please Inquire In Stock

Quality Control of Benzofuroxan

Number of papers citing our products

Chemical structure

Benzofuroxan

3D structure

Chemical Properties of Benzofuroxan

Cas No. 480-96-6 SDF Download SDF
PubChem ID 68075 Appearance Powder
Formula C6H4N2O2 M.Wt 136
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name 3-oxido-2,1,3-benzoxadiazol-3-ium
SMILES C1=CC2=NO[N+](=C2C=C1)[O-]
Standard InChIKey OKEAMBAZBICIFP-UHFFFAOYSA-N
Standard InChI InChI=1S/C6H4N2O2/c9-8-6-4-2-1-3-5(6)7-10-8/h1-4H
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Benzofuroxan Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Benzofuroxan Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Benzofuroxan

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 7.3529 mL 36.7647 mL 73.5294 mL 147.0588 mL 183.8235 mL
5 mM 1.4706 mL 7.3529 mL 14.7059 mL 29.4118 mL 36.7647 mL
10 mM 0.7353 mL 3.6765 mL 7.3529 mL 14.7059 mL 18.3824 mL
50 mM 0.1471 mL 0.7353 mL 1.4706 mL 2.9412 mL 3.6765 mL
100 mM 0.0735 mL 0.3676 mL 0.7353 mL 1.4706 mL 1.8382 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Benzofuroxan

Solvent-Mediated Functionalization of Benzofuroxan on Electron-Rich Ruthenium Complex Platform.[Pubmed:29645363]

Chem Asian J. 2018 Jun 18;13(12):1582-1593.

An unprecedented reactivity profile of biochemically relevant R-Benzofuroxan (R=H, Me, Cl), with high structural diversity and molecular complexity on a selective {Ru(acac)2 } (acac=acetylacetonate) platform, in conjugation with EtOH solvent mediation, is revealed. This led to the development of monomeric [Ru(III) (acac)2 (L(1R) )] (1 a-1 c; L(1R) =2-nitrosoanilido derivatives) and dimeric [{Ru(II) (acac)2 }2 (L(2R) )] (2 a-2 b; L(2R) =(1E,2E)-N(1) ,N(2) -bis(2-nitrosophenyl)ethane-1,2-diimine derivatives) complexes in one pot with a change in the metal redox conditions. The functionalization of Benzofuroxan in 1 and 2 implied in situ reduction of N=O to NH(-) in the former and solvent-assisted multiple N-C coupling in the latter. The aforesaid transformation processes were authenticated through structural elucidation of representative complexes, and evaluated by their spectroscopic/electrochemical features, along with C2 D5 OD labeling and monitoring of the impact of substituents (R) in the Benzofuroxan framework on the product distribution process. The noninnocent potential of newly developed L(1) and L(2) in 1 and 2, respectively, was also probed by spectroelectrochemistry in combination with DFT calculations.

Ruthenium-Hydride Mediated Unsymmetrical Cleavage of Benzofuroxan to 2-Nitroanilido with Varying Coordination Mode.[Pubmed:28825793]

Inorg Chem. 2017 Sep 5;56(17):10735-10747.

The reaction of R-Benzofuroxan (R = H, Me, Cl) with the metal precursor [Ru(Cl)(H)(CO)(PPh3)3] (A) or [Ru(Cl)(H)(CH3CN)(CO)(PPh3)2] (B) in CH3CN at 298 K resulted in the intermediate complex [Ru(Cl)(L(1))(CH3CN)(CO)(PPh3)2] (L(1) = monodentate 2-nitroanilido) (1, pink), which however underwent slow transformation to the final product [Ru(Cl)(L(2))(CO)(PPh3)2] (L(2) = bidentate 2-nitroanilido) (2, green). On the contrary, the same reaction in refluxing CH3CN directly yielded 2 without any tractable intermediate 1. Structural characterization of the intermediates 1a-1c and the corresponding final products 2a-2c (R = H, Me, Cl) authenticated their identities, revealing ruthenium-hydride mediated unsymmetrical cleavage of Benzofuroxan to hydrogen bonded monodentate 2-nitroanilido (L(1)) in the former and bidentate 2-nitroanilido (L(2)) in the latter. The spectrophotometric monitoring of the transformations of B --> 1 as well as 1 --> 2 with time and temperature established the first order rate process with associatively activated pathway for both cases. Both 1 and 2 exhibited one reversible oxidation and an irreversible reduction within +/-1.5 V versus saturated calomel reference electrode in CH3CN with slight variation in potential based on substituents in the Benzofuroxan framework (R = H, Me, Cl). Spectroscopic (electron paramagnetic resonance and UV-vis) and density functional theory calculations collectively suggested varying contribution of metal based orbitals along with the ligand in the singly occupied molecular orbital of 1(+) or 2(+), ascertaining the noninnocent potential of the in situ generated (L(1)) or (L(2)).

Novel Structural Hybrids on the Base of Benzofuroxans and Furoxans. Mini-Review.[Pubmed:27697059]

Curr Top Med Chem. 2017;17(9):986-1005.

Hybrid drug strategy is based on the combination of two or more pharmacophores into a new chemical entity to improve the properties of the original compounds or to obtain double action of resulting molecule. Hybrid molecules, comprised of some pharmacophore and nitric oxide (NO) donor moiety, constitute one of the more promising approaches for the design of drugs. Furoxans and Benzofuroxans are considered NO releasing prodrugs and are of great interest for researchers. In this review we will focus on furoxan and Benzofuroxan hybrids described in literature during the last years (from 2005 to 2016).

BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity.[Pubmed:26876618]

Toxicol Appl Pharmacol. 2016 Mar 15;295:56-67.

Benzofuroxan is an interesting ring system, which has shown a wide spectrum of biological responses against tumor cell lines. We investigated, herein, the antitumor effects of Benzofuroxan derivatives (BFDs) in vitro and in a melanoma mouse model. Cytotoxic effects of twenty-two BFDs were determined by MTT assay. Effects of BFD-22 in apoptosis and cell proliferation were evaluated using Annexin V-FITC/PI and CFSE staining. In addition, the effects in the cell cycle were assessed. Flow cytometry, western blot, and fluorescence microscopy analysis were employed to investigate the apoptosis-related proteins and the BRAF signaling. Cell motility was also exploited through cell invasion and migration assays. Molecular docking approach was performed in order to verify the BFD-22 binding mode into the ATP catalytic site of BRAF kinase. Moreover, the BFD-22 antitumor effects were evaluated in a melanoma murine model using B16F10. BFD-22 was identified as a potential hit against melanoma cells. BFD-22 induced apoptosis and inhibited cell proliferation of B16F10 cells. BFD-22 has suppressed, indeed, the migratory and invasive behavior of B16F10 cells. Cyclin D1 and CDK4 expression were reduced leading to cell cycle arrest at G0/G1 phase. Of note, phosphorylation of BRAF at Ser338 was strongly down-regulated by BFD-22 in B16F10 cells. The accommodation/orientation into the binding site of BRAF was similar of BAY43-9006 (co-crystallized inhibitor of BRAF, sorafenib). Importantly, BFD-22 presented in vivo antimetastatic effects and showed better therapeutic efficacy than sorafenib and taxol. BFD-22 can be considered as a new lead compound and, then, can be helpful for the designing of novel drug candidates to treat melanoma.

Synthesis of New 'Hybrid' Compounds Based on Benzofuroxans and Aminoalkylnaphthalimides.[Pubmed:26575416]

Chem Biol Drug Des. 2016 Apr;87(4):626-34.

Pathogenic bacteria and fungi eventually develop resistance to existing drugs, and therefore, we need constant development of new drugs. The research is aimed at addressing fundamental scientific problems-the search for new biologically active compounds among several Benzofuroxan-containing 'hybrid' products. N-substituted naphthalimides were chosen as a second pharmacophore. Benzofuroxanes biological effects were studied by means of bacterial lux-biosensors. Compounds IIIa, IVa, IIIc, and IVc displayed more expressed bacteriotoxic action in comparison with the initial substances Ia-c and represent a certain interest for using as antibacterial substances.

Benzofuroxan derivatives N-Br and N-I induce intrinsic apoptosis in melanoma cells by regulating AKT/BIM signaling and display anti metastatic activity in vivo.[Pubmed:26503030]

BMC Cancer. 2015 Oct 27;15:807.

BACKGROUND: Malignant melanoma is an aggressive type of skin cancer, and despite recent advances in treatment, the survival rate of the metastatic form remains low. Nifuroxazide analogues are drugs based on the substitution of the nitrofuran group by Benzofuroxan, in view of the pharmacophore similarity of the nitro group, improving bioavailability, with higher intrinsic activity and less toxicity. Benzofuroxan activity involves the intracellular production of free-radical species. In the present work, we evaluated the antitumor effects of different Benzofuroxan derivatives in a murine melanoma model. METHODS: B16F10-Nex2 melanoma cells were used to investigate the antitumor effects of Benzofuroxan derivatives in vitro and in a syngeneic melanoma model in C57Bl/6 mice. Cytotoxicity, morphological changes and reactive oxygen species (ROS) were assessed by a diphenyltetrasolium reagent, optical and fluorescence microscopy, respectively. Annexin-V binding and mitochondrial integrity were analyzed by flow cytometry. Western blotting and colorimetry identified cell signaling proteins. RESULTS: Benzofuroxan N-Br and N-I derivatives were active against murine and human tumor cell lines, exerting significant protection against metastatic melanoma in a syngeneic model. N-Br and N-I induce apoptosis in melanoma cells, evidenced by specific morphological changes, DNA condensation and degradation, and phosphatidylserine translocation in the plasma membrane. The intrinsic mitochondrial pathway in B16F10-Nex2 cells is suggested owing to reduced outer membrane potential in mitochondria, followed by caspase -9, -3 activation and cleavage of PARP. The cytotoxicity of N-Br and N-I in B16F10-Nex2 cells is mediated by the generation of ROS, inhibited by pre-incubation of the cells with N-acetylcysteine (NAC). The induction of ROS by N-Br and N-I resulted in the inhibition of AKT activation, an important molecule related to tumor cell survival, followed by upregulation of BIM. CONCLUSION: We conclude that N-Br and N-I are promising agents aiming at cancer treatment. They may be useful in melanoma therapy as inducers of intrinsic apoptosis and by exerting significant antitumor activity against metastatic melanoma, as presently shown in syngeneic mice.

Keywords:

Benzofuroxan,480-96-6,Natural Products, buy Benzofuroxan , Benzofuroxan supplier , purchase Benzofuroxan , Benzofuroxan cost , Benzofuroxan manufacturer , order Benzofuroxan , high purity Benzofuroxan

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: